Comparative Pharmacology
Head-to-head clinical analysis: ALYACEN 7 7 7 versus BREYNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYACEN 7 7 7 versus BREYNA.
ALYACEN 7/7/7 vs BREYNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
BREYNA is a contraceptive vaginal ring that releases ethinyl estradiol and etonogestrel. Etonogestrel is a progestogen that inhibits ovulation by suppressing gonadotropin release. Ethinyl estradiol enhances the contraceptive effect by stabilizing the endometrium and increasing cervical mucus viscosity.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
1 mg subcutaneously twice daily
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life is 12 hours; in patients with moderate to severe renal impairment, half-life may be prolonged up to 24 hours, requiring dose adjustment
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Primarily renal excretion of unchanged drug (approximately 70%) and biliary/fecal elimination (approximately 30%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive